American Society of Hematology

About the ASH Agenda

The field of hematology has experienced meaningful advances in quality of care thanks to the development of novel technologies, mechanistic insights, and cutting-edge therapeutic strategies. These foundational insights are reframing modern research with the continued goal of improving outcomes and discovering cures for the most challenging hematologic diseases.

Whereas some blood disorders have benefited from tremendous progress in clinical research and development of new therapies, other areas have continuing challenges, such as disease heterogeneity and the complex combinations of genetic drivers that have evaded effective treatment to date. A wide variety of blood-related diseases – from malignancies such as lymphoma and leukemia to non-malignant diseases such as hemoglobinopathies, platelet and coagulation disorders, and orphan diseases of the hematopoietic system – continue to be associated with significant morbidity and mortality and demand attention to reduce their burden and improve quality of care worldwide.

Today, the research community looks to emerging technologies and tools in the areas of precision medicine, epigenetics, gene therapies, immunotherapy, and regenerative medicine to identify areas that have strong potential to make a dramatic impact on patient care across a range of diseases.

The ASH Agenda for Hematology Research serves as a roadmap for the prioritization of research support across the hematology community, including recommendations for dedicated resources from funding agencies and foundations that will equip researchers today and in the future to make practice-changing discoveries. These specific and critically important research questions must be answered to gain insights that will launch the field into the next generation of therapies for hematologic conditions.

back to top